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Abstract 
Protein–lipid binding interactions play crucial roles in various physiological and 
pathological processes, making it very important to study these interactions at the 
molecular level. However, investigation of these interactions is complicated by several 
issues, including the inherent complexity of membranes as well as the diverse 
mechanisms by which proteins interact with the membrane surfaces. As a result, many 
of these interactions remain poorly characterized.  
Synthetic probes are useful tools employed for studying protein–lipid binding 
interactions. This thesis will detail the design and synthesis of metabolically stabilized 
analogues of various signaling lipids, which mimic the natural species and are not easily 
modified by enzymes present in biological systems. A modular approach is employed 
for synthesizing these lipid probes, giving access to a wide range of derivatized lipid 
probes that can then be used for several studies. 
Although a wide variety of metabolically stabilized lipid analogues have been 
synthesized, their activity has not yet been characterized and quantified in detail. So, 
there is a great need to synthesize biologically active phosphorothioate and 
phosphonate analogues of various signaling lipids in order to properly characterize and 
compare the binding affinities and activity of these analogues. Synthesis of 
metabolically stabilized lipid analogue would take us one step closer towards 
understanding protein–lipid interactions in biological systems and in trying to find 
answers to the myriad of questions pertaining to these systems. 
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Chapter 1: Introduction 
 
Lipid bilayers that comprise the core of cellular membranes have highly polarized 
structures consisting of central non-polar hydrocarbon core regions and two polar 
flanking interfacial regions.1 The interfacial regions consist of a complex mixture of 
water, phosphate groups, headgroups, and the polar portion of the acyl chains.2 (Figure 
1.1.) 
The lipids comprising cellular membranes not only serve roles in controlling the 
structure and fluidity of the membrane, but also play critical role as signaling molecules 
and modifiers of membrane protein function.3,3b   Based on their function, lipids can be 
categorized into two types: (a) bulk lipids, such as phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), and phosphatidylserine (PS) that comprise for majority 
of the lipid composition and are responsible for providing structure to the cell 
membranes, and (b) signaling lipids, such as diacylglycerol (DAG),2,4,5 phosphatidic acid 
(PA),6,7,8 and the phosphoinositides (PIPns) 6, 9,10 which are present in low percentages 
in cellular membranes, but are known to acts as key regulators in numerous biological 
processes.   
One important role that signaling lipids play is their involvement as site-specific 
ligands for attachment of peripheral protein receptors onto the membrane surface, a 
process that generally regulates protein function either by controlling enzyme activity 
directly, or by localizing proteins to particular intracellular compartments where they  
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Figure 1.1. Lipid bilayers of cell membranes showing the general phospholipid   
                   structure and a PA lipid probe containing a photoaffinity tag. 
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perform a specialized role.2,5,11 A large number of peripheral proteins contain one or 
more modular domains specialized in lipid binding. These lipid-binding domains, 
including the C1, C2, PH, and PX domains, recognize specific lipid molecules in the 
membranes and achieve signal transduction and subcellular localization. (Figure 1.2.) 
Such protein–lipid binding interactions play diverse roles in the regulation of 
protein trafficking, signaling and in disease onset. In order to fully understand the role 
these interactions play in essential biological processes, in cell signaling pathways, and 
in diseases such as cancer and diabetes, it becomes crucial to understand the nature of 
these interactions at the molecular level. 
However, investigation of these interactions is complicated by several issues, 
including the inherent complexity of membranes due to their heterogeneous nature as 
well as the diverse mechanisms by which proteins interact with membrane surfaces. 
Lipids comprising the membrane are targeted by a diverse array of protein-binding  
 
Figure 1.2. A peripheral protein targeting two signaling lipids via different binding  
                   domains. 
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modules, as is the case with PIPns which are known to bind to a wide array of proteins 
containing specialized PIPn-binding modules, such as the PH,9 PX, FYVE, ENTH, 
ANTH, FERM, Tubby, and PROPPIN12 domains.10, 13,14 Then there are variations even 
within the domain families as has been exemplified by investigations that indicate there 
are over 250 PH domains, indicating further complexity.14 PIPns affinities  and  
specificities are also known  to  vary widely amongst the various PIPns-binding modules 
based on the diversity in the binding mode, requiring  the  careful  investigation  of  each  
distinct receptor with each PIPn isomer.  
Our approach for studying protein–lipid interactions employs the synthesis of lipid 
probes mimicking natural species that can be effectively modified at a later stage of 
synthesis giving access to a wide range of derivatized target probe structures. This 
approach is advantageous as it provides access to a range of probes that can be used 
for several studies.  
Click chemistry is one such technique utilized for synthesizing derivatized lipid 
probes. The concept of click chemistry was proposed by Sharpless, Finn, and Kolb15 in 
2001, which employed an innovative approach for the synthesis of target molecules. 
Instead of focusing on the formation of difficult bonds, their approach involved exploring 
those reactions that are inherently efficient at linking two components. Such reactions 
must be fast, efficient, high yielding and should occur under ambient conditions. They 
termed such reactions as “click reactions”.  Since then, click reactions have been 
applied in diverse areas, including drug discovery,16,17 materials science,18 and chemical 
biology. In chemical biology, bioorthogonal click reactions have been used in the 
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selective labeling and detection of biomolecules such as protein,19,20 glycans,21 DNA, 
RNA22,23,24 and lipids25,26 in cell extracts and in living organisms. In order to take 
advantage of the click reactions for biomolecule labeling, one of the two bioorthogonal 
functional groups, usually an azide or alkyne, must first be introduced into the 
biomolecule. Next, reporter groups such as fluorophores or affinity tags are attached to 
an azide or alkyne and the copper-catalyzed click reaction is used to attach them to the 
biomolecule for labeling purposes. (Figure 1.3.) 
It was in 2000 that Bertozzi and co-workers27 first introduced azide as a 
functional handle for bioorthogonal click reactions.  Since then, azide and alkyne groups 
have been extensively used in click reactions as their small size results in minor 
structural perturbation, and they possess high intrinsic reactivity, yet are quite selective 
in the manner in which they react. They are stable to water, acidic and basic conditions, 
yet reactive enough to efficiently undergo bioorthogonal 1,3-dipolar cycloaddition (“click” 
chemistry)28 or Staudinger ligation.27, 29 All these factors render these reactions as 
invaluable tools for the labeling of biomolecules. Schultz and co-workers27, 30 recently 
 
Figure 1.3. Bioorthogonal labeling of an azide tagged lipid probe with reporter group  
                   via click reaction. 
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carried out selective in vivo labeling and optical detection of  phosphatidic acid probes 
bearing reactive tags. They attached a cyclooctyne moiety at the end of the sn-1 
position of the acyl chain. The probe was introduced into the cell, and copper-free click 
chemistry was used to attach the reporter groups for selective in vivo labeling of the lipid 
probe.  
Click chemistry can also be used for derivatization of lipid probes. This involves 
the synthesis of lipid scaffolds attached to an azide or alkyne tag, which can then be 
used for late-stage derivatization via bioorthogonal azide–alkyne click reaction. (Figure 
1.3.) Our lab has successfully used this approach to derivatize azide-tagged PA probes. 
For this, click chemistry was utilized to introduce fluorescent reporters or benzophenone  
photoaffinity tags onto the azide-tagged PA probe to synthesize a wide array of lipid 
probes.25 Synthesis of a bifunctional PA analogue attached to a benzophenone moiety 
and an azide moiety was also reported, which will be used for activity based protein 
profiling (ABPP) to purify, identify and characterize proteins that interact with the target 
lipid probes. 
ABPP is an important approach that makes use of small molecules called activity 
based probes (ABPs) for specific labeling of the enzyme targets, biochemical profiling of 
diverse proteomes, and direct imaging and monitoring of enzyme activity in biological 
system. ABPs  are  designed  to  interact  with  active-site residues of enzymes resulting 
in the formation of a stable covalent bond, allowing for the enzyme  adduct to  be  
visualized or  isolated  and  identified. An ABP is usually comprised of: 1) a reactive  
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Figure 1.4. An illustration of ABPP using an ABP consisting of a reactive group,  
                   spacer and a tag. 
 
group, which could be an electrophile or a photoactive group that attaches the probe to 
the enzyme active site, 2) a flexible linker/spacer that connects the reactive group with 
the reporter tag 3) a reporter tag, which could be a fluorophore for visualization or 
affinity tag like biotin for isolation, purification and characterization. (Figure 1.4.) In order 
to increase the versatility of ABPs, several groups have utilized synthetic handles such 
as azide and alkyne to incorporate reporter groups via click chemistry for post-labeling 
the proteins. An advantage of this approach is that it reduces the size of the ABP, 
making its incorporation into the cell easy since the ABP is no longer attached to the 
large fluorophores or affinity tags. Wright and  Cravatt31  have synthesized  ABPs 
having an alkyne handle. Once the probe was attached to the enzyme cytochrome 
P450 by reaction of the electrophilic reporter group with the nucleophilic residue of the 
active site, the alkyne handle was then used to attach rhodamine or biotin reporter tags 
both for in vivo and in vitro studies. (Figure 1.5.) Wang and co-workers32 have 
synthesized bifunctional ABPs for labeling metalloproteases, containing a 
benzophenone photocrosslinker and a rhodamine fluorophore.  
Reactive
Group
Spacer Tag
Tag
Tag = azide / alkyne / fluorophore / aff inity tag
Selective labelling of the active
site of protein by a probe
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Figure 1.5. Various Activity-Based Probes (ABPs). 
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Kroon and co-workers33 have synthesized bifunctional probes of phosphatidylcholine, 
making use of phenylazide or benzophenone as the photoactivatable group for covalent 
binding of the protein and an azide tag in the lipid tail to attach biotin or rhodamine for 
post labeling the protein in order to  purify or visualize the proteins respectively. (Figure 
1.5.) 
Metabolically Stabilized Lipid Analogues 
An important concern regarding the use of synthetic probes in biological systems 
is that these probes can be easily modified by various enzymes present in the biological 
systems so that the original probe is no longer being studied. There has been 
considerable amount of interest in synthesizing ‘‘metabolically stabilized analogues’’ 
where the labile structural elements of naturally occurring compounds are chemically 
stabilized. The phosphate group, an integral part of many important biomolecules such 
as  nucleotides  and  phospholipids,  is  considered  to  be  a  very  labile  moiety  and is  
susceptible to hydrolysis by several enzymes. Attempts have been made at making the 
phosphate group resistant to enzymes without greatly affecting the binding properties. 
In this regard, phosphorothioates were the first metabolically stabilized phosphomimetic 
group to be used to replace the phosphate group. This involves replacing P=O with a 
P=S bond in the phosphate group. (Figure 1.6.) Eckstein and co-workers34 first 
introduced this group into nucleosides and found the corresponding analogues resistant 
to phosphate hydrolysis without greatly affecting the binding properties.35  
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Figure 1.6. Various metabolically stabilized phosphomimetic groups. 
 
Since then, interest in enzymatically resistant analogues has risen substantially, 
and many phosphorothioate analogues, particularly those of signaling lipids such as 
PIPns,36,36b LPA37,38 and cPA37 have been synthesized. Okruszek and co-workers37 
have recently synthesized phosphorothioate/phosphorodithioate derivatives of 
lysophosphatidic acids (LPA) 1 and cyclic phosphatidic acids (cPA) 2. (Figure 1.7) The 
preliminary experiments performed on unmodified phosphate and  phosphorothioate  
cPA  show  both analogues to be stable after 48h incubation  in thermally inactivated 
bovine fetal serum or in human serum.  Prestwich and co-workers36b have synthesized 
and studied the binding affinities of various phosphorothioate stabilized PI(3,4,5)P3 
towards the pH domain containing protein GRP. These metabolically stabilized  
PI(3,4,5)P3 analogues have  phosphorothioate  groups in  place  of  the  phosphate  
group at position 3, position 5, and position 3, 4 and 5. (Figure 1.7. structure 3, 4 and 5 
respectively)  
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Figure 1.7. Various metabolically stabilized lipid analogues. 
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They observed that while the  3-, and 5- stabilized phosphorothioate showed equivalent 
binding to unmodified PI(3,4,5)P3, the 3,4,5 stabilized phosphorothioate showed 
reduced binding affinities. This was mainly attributed to the modified pKa and decreased 
hydrogen-bonding ability of phosphorothioate compared to phosphate.39     
Another phosphomimetic group used to replace the natural phosphates is the   
phosphonate group.  Phosphonate analogues are formed by replacing the bridging 
oxygen or one of the phosphate oxygens with methylene or methyl groups. (Figure 1.6.) 
Prestwich and co-workers have synthesized methylphosphonate analogues as 
potentially useful phosphatase-resistant ligands for various PIPns, such as  
phosphatidylinositol 3-phosphate PI(3)P 6, 40 phosphatidylinositol 5-phosphate PI(5)P 
7,41 and phosphatidylinositol 3,4,5-trisphosphate PI(3,4,5)P3.42 Prestwich and co-
workers36b  studied the binding affinities of different PI(3,4,5)P3  and observed that these 
compounds  also exhibited  weaker  binding  to  receptor  domains  when  compared  to  
natural PI(3,4,5)P3. This was attributed to the modified second pKa value of 
phosphonates compared to natural phosphates.  
In order to improve the binding affinities of phosphonates, fluoromethylene 
phosphonates can also be used to replace the phosphate group. Fluoromethylene 
phosphonates have a second pKa value similar to that of natural phosphonate because 
of the presence of  the electron- withdrawing  fluorine  group  that decreases the pKa.43  
The fluoromethylene phosphonate group has also been successfully incorporated in 
PIPns, PA and LPA to produce biologically active analogues. Fluoromethylene 
phosphonates of LPA and cPA have been synthesized, and their agonist and antagonist 
13 
 
activity studied.43 (Figure 1.7.)  The acyclic α-fluoromethylene phosphonate of LPA 8 
was found to be a potent LPA 3 agonist, while its cyclic analogue 9 (cPA) was found to 
be a selective LPA1/3 antagonist. Also, upon cyclization to 11 the inactive acyclic α,α-
difluoromethylene phosphonate 10 became a weak LPA 1/2/3 agonist. Prestwich and co-
workers44 have also synthesized monofluorinated and difluorinated PA phosphonate 
analogues that are resistant to the phosphatase activity and have been found to 
stimulate mTOR signaling pathways similar to PA in quiescent HEK 293 cells. 
Due to the crucial role that protein–lipid binding interactions play in various 
physiological and pathological processes, it is very important to study these interactions 
at the molecular level. Synthetic probes are useful tools that can be employed for 
labeling and identifying various protein receptors involved in disease onset. Although a 
wide variety of metabolically stabilized lipid analogues have been synthesized, their 
activity has not yet been characterized and quantified in detail. So, there is a great need 
to synthesize metabolically stabilized analogues of various signaling lipids in order to 
properly characterize and compare the binding affinities and activity of these analogues. 
Synthesis of metabolically stabilized lipid analogue would help us in understanding 
protein–lipid interaction in the biological systems and in trying to find answers to the 
myriad of questions pertaining to these systems. 
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Chapter 2: Design and Synthesis of Metabolically Stabilized 
Phosphatidic Acid Analogues 
 
Background and significance  
Phosphatidic acid (PA) is an important signaling lipid that is present in small 
amounts in cell membranes but plays a crucial role in various physiological and 
pathological processes. Some important physiological functions include regulation of 
protein and lipid phosphorylation,45,46 membrane trafficking,47,6 and signal 
transduction.48 PA can act as a site-specific ligand that is specifically recognized by 
various protein receptors and plays an important role in cell signaling by regulating the 
function and subcellular localization of bound proteins. PA binds certain protein 
receptors including  Raf-1 kinase49 and certain isoforms of the protein kinase C (PKC) 
family, such as PKCα50 and PKCε51 that have been known to play vital roles in 
carcinogenesis. As such, it is very important to study protein–PA binding interactions at 
the molecular level.  
The chemical structure of PA consists of glycerol, to which two acyl chains and 
an anionic phosphate group are attached at the sn-1, sn-2 and sn-3 positions, 
respectively. (Figure 2.1.) It is this phosphate headgroup that is the defining feature of 
PA and sets it apart from other phospholipids. B. de Kruijff and co-workers52 have 
presented an electrostatic hydrogen bond switch mechanism to explain the specificity of 
PA toward binding. They showed that the monoprotonated PA is initially stabilized by an  
15 
 
 
Figure 2.1. General structure of phosphatidic acid. 
 
intramolecular hydrogen bond. The proteins and peptides having basic residues 
specifically associate to the membrane via electrostatic attraction. This is followed by  
hydrogen-bond  formation  between  the  receptor  and  PA headgroup, resulting in full 
phosphate deprotonation ( -2 charge). This charge enhances association and provides 
binding specificity. The shape of PA is also believed to contribute to binding specificity.  
At physiological pH, PA exists as a cone-shaped structure. This results in the placement 
of the phosphate headgroup in the mildly polar interfacial region. 53 This  is  believed  to 
enhance  the  penetration  of  hydrophobic  residues  into  the membrane, resulting in 
improved binding. Thus, the specific placement of PA in the membrane and the 
ionization properties of this phosphomonoester headgroup result in the specificity of 
PA–protein interaction.  
Recent  studies have suggested that PA directly regulates the activities of some 
important signaling  molecules,  such  as  mTOR,54  Ras,55  neurogranin,56 and  
enzymes like PIP5-kinase,57 suggesting that PA is an important signaling lipid in cells. 
Many of these functions are mediated by the direct interaction of PA with specific target 
16 
 
proteins. There has been a considerable amount of interest in identifying proteins that 
interact with PA.  A  number  of  PA-binding  proteins  have  been  identified,  which 
include  protein kinases,57 protein phosphatases,58,59 and  cAMP-specific  
phosphodiesterases.60,61  
 Interestingly, when one compares the PA binding region of the receptor proteins, 
no consensus sequence common to the PA binding proteins can be found except for 
one    feature  that  is present in most PA-binding domains, which is the  presence  of  
basic  amino acid residues8,14 such as  arginine, lysine or tryptophan that specifically 
bind to PA.  Since structural approaches have not been very successful in the discovery 
of PA-binding receptors and the PA binding domains, synthetic approaches can play a 
crucial role in PA–protein binding interactions. Here, synthetic probes can be used for 
gaining important information about the precise spatial and temporal regulation of PA 
signaling. Incorporation of the reporter molecules with the lipid probes would facilitate in 
mapping the protein receptors and the binding domains that specifically bind to PA. This 
could possibly lead to the identification of some type of common sequence homology in 
the binding domains. It will also allow us to understand how PA-binding proteins 
specifically recognize PA amongst other anionic lipids.  
Towards this goal, a large number of PA probes have been synthesized so far. 
Ktistakis and co-workers62,63 have synthesized analogues of PA and immobilized them 
onto a solid support by means of an amino function attached at the end of the acyl tail at 
the sn-1 position of the glycerol moiety. PA-modified resin was then used as affinity 
matrices, to purify and identify a number of known proteins as well as some novel 
17 
 
proteins that bound specifically to PA. Nemoz and co-workers64 have synthesized PA 
analogues bearing a photoactivable group, 4-azidotetrafluorobenzylacyl either at the sn-
1 or sn-2 position of the fatty acyl chain. Upon UV irradiation, these polyfluorinated aryl 
azides can specifically and covalently link to the neighboring amino acid residues on the 
phosphodiesterases (PDE) peptide chain resulting in covalent labeling of the PDE 
enzymes. The analogues so obtained retain the ability of PA to activate the cAMP-
hydrolyzing enzyme PDE4D3 to varying degrees. Neef and Schultz30 recently 
developed a bifunctional PA probe with cyclooctyne incorporated at the end of the acyl 
tail at the sn-1 position. Once the probe was incorporated into living cells, the 
cyclooctyne was used to attach a fluorophore to the PA probe by means of copper-free 
click chemistry resulting in the labeling of the PA probe within the cell. 
Metabolically Stabilized PA Analogues 
 Cellular PA may be produced and degraded by several enzymes present in the 
living systems. These enzymes are subject to complex and tight regulation, and the 
timing of their production regulates the potential pathway that will be followed for PA 
production and degradation. PA can be formed by various pathways, such as hydrolysis 
of membrane phospholipids by PLD; phosphorylation of DAG by DGK; acyl transferase, 
to LPA; and from G3P and DHAP. (Figure 2.2.) PLD and DGK are the two principal 
enzymes that produce signaling PA.65,66  
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Figure 2.2. Synthesis and degradation of cellular PA by various enzymes.6  
 
PA is known to be metabolically labile and is susceptible to hydrolysis by several 
enzymes that can hydrolyze the phosphate group and the ester groups present in PA. It 
is possible to make PA metabolically stabilized in order to make it enzymatically 
resistant and to prolong its biological activity.  This  can  be  achieved by (a) the 
replacement of the acyl ester lipid chains with alkyl ether chains,67 and (b) by the 
strategic replacement of the phosphate group at the sn-3 position into  non-hydrolyzable 
phosphomimetic groups.44,68 The common types of phosphomimetic functional groups 
that are currently being used include phosphonates (methylene phosphonate, 
fluoromethylene phosphonate, phosphonothioate) and the phosphorothioates. 
There has been great interest in synthesizing metabolically stabilized lipid 
analogues of PA that provide it enzymatic resistance without greatly affecting its binding 
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properties. Interest in enzymatically resistant lipid analogues has risen substantially with 
the synthesis of a  large number of metabolically stabilized lipid analogues for various 
signaling lipids, such as PIPns,36,36b cPA,37,69 and LPA.37,38 Recently, this approach has 
been extended to synthesizing metabolically stabilized PA analogues. In this regard, 
Prestwich and co-workers44 have synthesized monofluorinated and difluorinated PA 
phosphonate analogues that are resistant to the phosphatase activity and have been 
found to stimulate mTOR signaling pathways similar to PA in quiescent HEK 293 cells. 
The difluoromethylene PA  analogue  was also found to act as an  inhibitor of LPP1 
activity, potentiate platelet aggregation and shape change responses to LPA and 
amplifiy LPA production by agonist-simulated platelets.68  
In conclusion, PA is an important signaling lipid and plays key roles in cell growth 
and protein trafficking via protein binding. Therefore, PA–protein binding interactions 
need to be probed further in order to discover PA binding receptors and to understand 
the specificity of these receptors towards PA. As such chemical probes would play a 
crucial role in understanding PA–protein interactions at the molecular level.  
Synthesis of Stabilized PA Lipid Analogues 
Our strategy for synthesizing metabolically stabilized PA analogues started with 
the introduction of a phosphorothioate in place of a phosphate group at the sn-3 
position. Phosphorothioate groups have previously been shown to be resistant to 
phosphate hydrolysis with minimal effect on binding properties.36 The only modification 
involved in the synthesis of phosphorothioates analogues of PA is the introduction of a 
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protected phosphorothioate rather than a protected phosphate, such that the same 
synthetic route used for the synthesis of regular PA probes can be utilized. The strategy 
adopted by our group for the PA lipid probe design involves the synthesis of modular PA 
scaffolds bearing an azide group at the sn-1 position, which can be functionalized with 
various reporter groups at a late stage via click chemistry to access a range of reporter 
group tagged lipid probes.  We attempted to make use of the same strategy for the 
synthesis of phosphorothioate analogues of PA. This involved the synthesis of a 
modular PA scaffold having a protected phosphorothiolates group at the sn-3 position 
and an azide tag at the sn-1 position that was used to attach a reporter tag via 
bioorthogonal azide–alkyne click reaction. The fluorophores help in studying protein–
lipid binding interactions by acting as Förster resonance energy transfer (FRET) pairs. 
FRET is a radiationless energy transfer from an excited donor molecule to an acceptor 
molecule through long-range (10–100 Å) dipole–dipole couplings.70 Therefore, for FRET 
to occur, the donor and acceptor should be present in close proximity as it is highly 
dependent upon the distance between them. The closer the donor is to the acceptor, 
the more FRET is observed and vice versa. Thus, FRET is a useful technique for 
detecting changes in proximity between the donor and acceptor.  
The final synthesis, shown in figure 2.3., first involved the protection of the diol of 
the commercially available diethyl L-tartrate 12 using cyclopentylidene to give 13. The 
esters were then reduced using lithium aluminum hydride to form 14.71 Compound 14  
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Figure 2.3. Synthesis of phosphorothioate-stabilized PA probe attached to a    
                   fluorescent tag. 
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was then selectively mono-tosylated, followed by its substitution with azide71b, 72 to 
furnish 15. This was followed by the installation of a protected phosphorothioate group 
at the sn-3 using dibenzyl diisopropylphosphoramidite 16 and sulfur to afford 17.73 The 
cyclopentylidene acetal was then removed under acidic conditions using p-
toluenesulfonic acid to yield diol 18. The ester tails were then coupled on to the diol to 
furnish protected phosphorothioates PA scaffold 19.  
Once the protected PA scaffold 19 was synthesized, we now sought to install a 
reporter group to the core scaffold utilizing the bioorthogonal click reaction between the 
azide-tagged PA scaffold and naphthyl alkyne 20 in order to obtain a phosphorothioate 
PA probe. We encountered problems with the click reaction, which proceeded in very 
low yields. We unsuccessfully attempted to improve the yield either by using a 
polytriazole ligand (synthesized by Meng M. Rowland),  known to act as a copper(I)-
stabilizing ligand in catalysis and protect it from oxidation and disproportionation, while 
enhancing its catalytic activity,74 or by using copper fluoride as an alternative reagent for 
the click reaction. We then went back to the original conditions employed for the click 
reaction. After functionalizing the protected phosphorothioate PA scaffold with a 
fluorophore to yield 21, we then tried to deprotect the benzyl groups on the protected 
phosphorothioate moiety with bromotrimethylsilane (TMSBr) to produce PA probe 22.  
In the case of phosphorothioates, it was observed that deprotection by TMSBr never 
went to completion even after prolonged reaction times. There have been other similar 
reports where it has been observed that TMSBr is not a good deprotecting reagent for 
the benzyl groups in case of the phosphorothioates.36a  
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These problems made us rethink our strategy for synthesizing metabolically 
stabilized PA probes. Instead of focusing on one kind of phosphomimetic group, which 
would require that each probe be synthesized in an individual manner, we started out 
with designing a synthetic strategy that would allow us to access a wide range of 
metabolically stabilized PA probes from a common scaffold. Many metabolically 
stabilized lipid analogues have been synthesized, but their activity and binding 
properties have not yet been quantified.  
In order to study and compare various phosphomimetic groups, we first 
synthesized a very simple DAG scaffold without an azide tag, which was then 
derivatized to form various PA analogues. This was done to simplify the synthesis of the 
PA analogues. We also replaced the ester-linked acyl tails of PA with the ether-linked 
tails. This change solved some of the problems that we had faced while designing a 
modular approach for PA probe synthesis that involved installing a phosphate group 
onto the core DAG scaffold at a late stage of synthesis. Earlier, in our lab, attempts 
have been made based on this approach, but these were not successful because of the 
sn-2 to sn-3 acyl migration that was observed in the final deprotection step of the DAG 
synthesis and while installing the phosphate head groups.26,25 (Figure 2.4.) The 
migration is known to be catalyzed via both acid and base mechanisms, as well as 
being facilitated by prolonged exposure to silica gel.75 Also, since the removal of 
common lipid protecting groups such as PMB and TBDPS occur via basic mechanisms, 
it further promotes the migration. 
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Figure 2.4. Migration of the sn-2 acyl chain upon removal of the sn-3 protecting   
                   group in an azide tagged DAG scaffold. 
 
Using a new approach that involves replacing of acyl tails with the ether tails, the 
problem of acyl migration can be altogether avoided. This approach allows us to access 
a wide range of PA probes simply by derivatizing the DAG having ether tails at a later 
stage with various metabolically stabilized phosphomimetic groups such as methylene 
phosphonates, fluoromethylene phosphonates, and phosphorothioates. Another 
advantage of using the ether tails instead of acyl tails is that they make the PA 
analogues resistant to lipases that specifically hydrolyze the esters of the acyl tails. 
 As show in Figure 2.5., the synthesis of DAG scaffold 27 with ether tails begins 
with the protection of the hydroxyl group of commercially available (S)-(+)-2,2-dimethyl-
1,3-dioxolane-4-methanol 23, with a p-methoxybenzyl  (PMB)  group  to  obtain  24.  
Next, the acetonide group is deprotected under acidic conditions to give 25. The ether 
tails were then introduced using 1-bromooctadecane and tetrabutylammonium iodide 
(TBAI) as a catalyst yielding 26.76   
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Figure 2.5. Modular synthetic scheme for the synthesis of metabolically stabilized  
                   PA probes. 
 
Oxidative removal of the PMB protecting group affords diacylglycerol analogue 27.  
Once the ether DAG scaffold was synthesized, we now sought to install various 
protected phosphomimetic groups onto the core DAG scaffold to give us 28(a-b) which 
were then deprotected to obtain metabolically stabilized PA probes  29(a-b). 
Experimental 
General Considerations 
All reagents were purchased from Aldrich and Acros and used as received. Dry solvents 
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were obtained from a Pure Solv solvent delivery system purchased from Innovative 
Technology, Inc. Column chromatography was performed using 230–400 mesh silica 
gel purchased from Sorbent Technologies. NMR spectra were obtained using a Bruker 
AC250 spectrometer updated with a TecMag data collection system, as a Varian 
Mercury 300 spectrometer. Mass spectra were obtained with a JEOL DART-AccuTOF 
spectrometer with high-resolution capabilities. Optical rotation values were obtained 
using a Perkin-Elmer 241 polarimeter.  
Synthetic Procedures 
(2R,3R)-diethyl 1,4-dioxaspiro[4.4]nonane-2,3-dicarboxylate (13). 
O
O O
O
O O
 
Diethyl L-tartrate 12 (3.37 mL, 19.6 mmol) was dissolved in toluene (130 mL). To this 
solution was added cyclopentanone (8.7 mL, 98 mmol) and p-toluenesulfonic acid (373 
mg, 1.96 mmol). A Dean–Stark trap was attached and the reaction was heated at 150 
°C overnight. Solid sodium bicarbonate (329 mg, 20%) was added and stirring was 
continued for 15 min. The reaction mixture was filtered and concentrated under reduced 
pressure. Column chromatography with silica gel and gradient elution with 0–20% ethyl 
acetate to hexanes afforded 13 as a yellow oil (3.89 g, 73%). 
Characterizations matched those reported in the literature.25  
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(2S,3S)-1,4-dioxaspiro[4.4]nonane-2,3-diyldimethanol (14).  
 
Diester 13 (3.1 g, 11.5 mmol), dissolved in anhydrous THF (10 mL), was added 
dropwise to a solution of lithium aluminum hydride (875 mg, 23.3 mmol) in anhydrous 
THF (20 mL)  at 0 °C under nitrogen. After the addition was complete, stirring was 
continued for 1 h at 0 °C and then at room temperature for an additional 1 h. The 
solution was cooled to  0 °C and to it was slowly added, water (1.34 mL), 10% NaOH 
(1.34 mL), and water (2.7 mL) to quench the reaction. After addition, stirring was 
continued for 30 min at room temperature. Anhydrous magnesium sulfate was added 
and stirring was continued for another 30 min. The solution was filtered and 
concentrated under reduced pressure. Column chromatography with silica gel and 
gradient elution with 0–10% methanol to dichloromethane afforded 14 as a clear oil 
(1.79 g, 83%). 
Characterizations matched those reported in the literature.25 
((2S,3S)-3-azidomethyl)-1,4-dioxaspiro[4.4]nonan-2-yl)methanol (15).   
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Diol 14 (1.77 g, 9.50 mmol) was dissolved in dichloromethane (20 mL). To the solution 
was added silver(I)oxide (3.30 g, 14.2 mmol), tosyl chloride (1.9 g, 10.1 mmol) and 
potassium iodide (315 mg, 1.92 mmol). The resulting solution was stirred at room 
temperature for 2 h and then filtered through a plug of silica gel with 100% ethyl acetate 
as the eluant. The filtrate was concentrated under reduced pressure, and then dissolved 
in DMF (95 mL). To the stirring solution was added sodium azide (1.55 g, 23.7 mmol). 
The solution was stirred at 85 °C overnight, concentrated, extracted with chloroform (2 x 
100 mL), dried with magnesium sulfate, and concentrated under reduced pressure. 
Column chromatography with silica gel and 50% ethyl acetate to hexanes as eluant 
afforded 15 as a clear oil (1.30 g, 64%).  
Characterizations matched those reported in the literature.25 
 O-(((2S,3S)-3-(azidomethyl)-1,4-dioxaspiro[4.4]nonan-2-yl)methyl) O,O-dibenzyl    
phosphorothioate (17). 
 
Azido alcohol 15 (114 mg, 0.53 mmol) was dissolved in anhydrous dichloromethane (4 
mL). 1H-tetrazole (3.56 mL, 1.60 mmol, 0.45 M stock) was added and the solution was 
cooled to 0 °C under nitrogen. Dibenzyl diisopropylphosphoramidite 16, (193 μL, 0.588 
mmol) was then added dropwise. Stirring was continued for 10 min at 0 °C and then at 
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room temperature for 2 h. The reaction mixture was cooled to 0 °C, and sulfur (69 mg, 
2.13 mmol), carbon disulfide (90 µL) and pyridine (90 µL) were added and stirring was 
continued for 24 h. The reaction was extracted with dichloromethane, dried with 
magnesium sulfate, filtered and concentrated under reduced pressure. Column 
chromatography with silica gel and 40% ethyl acetate to hexanes as eluant afforded 17 
as a pale-yellow oil (267 mg, 100%). 
1H NMR (300 MHz, CDCl3) δ 7.39–7.30 (m, 10H), 5.14–4.99 (m, 4H), 4.14–3.87 (m, 
4H), 3.42–3.35 (m, 1H), 3.22–3.15 (m, 1H), 1.83–1.64 (m, 8H); MALDI–HRMS [M + 
Na]+ calcd: 512.13850, found: 512.14184. 
O-((2S,3S)-4-azido-2,3-dihydroxybutyl) O,O-dibenzyl phosphorothioate (18). 
 
Compound 17 (46 mg, 0.093 mmol) was dissolved in methanol (1 mL). With stirring, p-
toluenesulfonic acid (12 mg, 0.06 mmol) was added. The solution was stirred at room 
temp overnight. The reaction was quenched with saturated sodium bicarbonate, 
extracted with chloroform (2 x 100 mL), dried with magnesium sulfate, filtered and 
concentrated under reduced pressure. Column chromatography with silica gel and 
gradient elution with 10–50% ethyl acetate to hexanes afforded 18 as a yellow oil (22 
mg, 55%). 
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1H NMR (300 MHz, CDCl3) δ 7.37–7.31 (m, 10H), 5.10–4.96 (m, 4H), 4.01–3.96 (m, 
2H), 3.66–3.59 (m, 2H), 3.32–3.12 (m, 4H); HRMS [M – N2 + H]+ calcd: 396.10346, 
found: 396.10496. 
(2S,3S)-1-azido-4-((bis(benzyloxy)phosphorothioyl)oxy)butane-2,3-diyl distearate 
(19).  
 
Stearic acid (294 mg, 1.034 mmol) was dissolved in dichloromethane (5 mL). To the 
stirring solution was added N,N-dicyclohexylcarbodiimide (213 mg, 1.03 mmol) and 4-
dimethylaminopyridine (42 mg, 0.34 mmol) and stirring was continued for 15 min. A 
white precipitate formed to which was added diol 18 (127 mg, 0.35 mmol) and the 
solution was stirred at room temperature overnight. The reaction was filtered and 
concentrated under reduced pressure. Column chromatography with silica gel and 
gradient elution with 10–25% ethyl acetate to hexanes afforded 19 as a white solid (820 
mg, 74%). 
1H NMR (300 MHz, CDCl3) δ 7.35–7.31 (m, 10H), 5.07–5.02 (m, 4H), 4.27–4.02 (m, 
2H), 2.30–2.21 (m, 4H), 1.70–1.50 (m, 4H), 1.36–1.16 (b s, 56H), 0.87 (m, 6H); MALDI–
HRMS [M + Na]+ calcd: 978.61348, found: 978.61792. 
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naphthyl alkyne (20).  
 
2-Naphthylacetic acid (100 mg, 0.537 mmol), N,N-dicyclohexylcarbodiimide (166.2 mg, 
0.806 mmol), 4-dimethylaminopyridine, (32.8 mg, 0.269 mmol) and propargylamine (44 
μL, 0.644 mmol) were dissolved in dichloromethane (6 mL). The reaction was stirred at 
room temperature in the dark overnight. The reaction was extracted with 
dichloromethane and water and the organic layer was dried with magnesium sulfate, 
filtered, and the solvent was removed by rotary evaporation. Column chromatography 
with silica gel and a gradient elution with 25–50% ethyl acetate to hexanes afforded 20 
as a white solid (95 mg, 79%). 
Characterizations matched the literature.25  
naphthyl phosphorothiotriester PA (21). 
 
Compound 19 (25 mg, 0.026 mmol) and naphthyl alkyne 20 (5.83 mg, 0.026 mmol) 
were dissolved in THF (0.7 mL). Copper sulfate pentahydrate (20 mg, 0.078 mmol) and 
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sodium ascorbate (31 mg, 0.156 mmol) were added along with H2O (0.3 mL). The 
solution was stirred at room temperature overnight. Then the solvent was removed 
under reduced pressure. Column chromatography with silica gel and a gradient solvent 
system of 20–50% ethyl acetate to hexanes afforded 21 as a white solid (12 mg, 11%). 
1H NMR (300 MHz, CDCl3) δ 7.76–7.70 (m, 3H), 7.62 (s, 1H), 7.42–7.36 (m, 3H), 7.26 
(m, 10H), 6.05–6.01 (m, 1H), 5.35–5.30 (m, 1H), 5.00–4.96 (m, 5H), 4.33–4.35 (m, 4H), 
4.09–4.05 (m, 2H), 3.65 (s, 2H), 2.23–2.13 (m, 2H), 1.61–1.40 (m, 4H), 1.18 (b s, 56H), 
0.81 (t, J = 6.49 Hz, 6H); MALDI–HRMS [M + Na]+ calcd: 1201.71319, found: 
1201.70253. 
naphthyl phosphorothioate PA (22).  
 
 Naphthyl phosphotriester 21 (27 mg, 0.029 mmol), was dissolved in dichloromethane 
(0.7 mL) at 0 °C under argon. Bromotrimethylsilane (387 µL) was added and stirring 
was continued at room temperature for 2 h. Solvent was removed under reduced 
pressure and the residue was placed on a high vacuum line to remove any residual 
solvents. Due to the amphipathic nature of the phosphorothiotriesters, the integration 
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values in the proton NMR were close to actual values but did not always correspond to 
the exact value.  
(S)-4-((4-methoxybenzyloxy)methyl)-2,2-dimethyl-1,3-dioxolane (24).  
 
Sodium  hydride  (0.256  g,  0.006  mol)   dissolved  in  N,N-dimethylformamide (30 mL) 
was taken in a round bottom flask under nitrogen and cooled to 0 °C.  (S)-(2,2-dimethyl-
1,3-dioxolan-4-yl)methanol 23 (0.5 mL, 0.004 mol) dissolved in DMF (10 mL) was added 
dropwise into the reaction mixture over a period of 30 min.  The  reaction  was  stirred  
at   0 °C for 1 h and then p-methoxybenzyl chloride (PMBCl, 813 µL, 0.006  mol)  was  
added  to  the  solution  at  0 °C  and stirred  at  room  temperature  overnight.  The 
reaction was quenched with water and extracted with dichloromethane and water (2 x 
150 mL), the organic layer was dried over magnesium sulfate, filtered, and the solvent 
was removed under reduced pressure. The next step was set up without further 
purification. 
(R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol (25). 
  
(S)-4-((4-methoxybenzyloxy)methyl)-2,2-dimethyl-1,3-dioxalane  24, (1.5  g,  5.95 mmol)  
was dissolved  in methanol (40mL) and p-toluenesulfonic acid (128 mg, 0.67 mmol) was 
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added to the reaction mixture and stirred at room temperature  overnight.  The  reaction  
was then quenched  with  saturated  sodium bicarbonate  followed  by  extraction  with  
dichloromethane  and  water (3 x 100 mL).  Column chromatography with silica gel and 
a gradient elution with 2–4% of methanol to dichloromethane afforded 25 as a yellow oil 
(1.2 g, 39% over 2 steps)  
Characterizations matched those reported in the literature.77 
(R)-1-((2,3-bis(octadecyloxy)propoxy)methyl)-4-methoxybenzene (26). 
 
Compound 25 (222 mg, 1.05 mmol) was dissolved in dry benzene (4 mL) followed by 
the addition of 1-bromooctadecane (1.09 mg, 3.13 mmol), potassium hydroxide (237 
mg, 4.22 mmol) and a catalytic amount of tetrabutylammonium iodide (TBAI).  The 
reaction was refluxed overnight at 105 °C and a Dean–Stark trap was used to collect 
water formed in the reaction. Column chromatography with silica gel and a gradient 
elution with 0–10% of ethyl acetate to hexanes afforded 26 as a white solid (552 mg, 
74%). 
1H NMR (300 MHz, CDCl3) δ 7.30–7.22 (m, 2H), 6.89–6.84 (m,  2H), 4.45 (d, J = 15.2 
Hz, 2H), 3.80 (s, 3H), 3.61–3.36 (m, 9H), 1.62–1.49 (m, 4H),  1.38–1.17 (b s, 60H), 0.88 
(t, J = 6.6 Hz, 6H);  MALDI–HRMS [M + Na]+ calcd: 739.65803, found: 739.65863. 
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(S)-2,3-bis(octadecyloxy)propan-1-ol (27). 
 
Compound 26 (550 mg, 0.76 mmol) was dissolved in dichloromethane (20 mL), and 
water (0.2 mL) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (812 mg, 3.83 
mmol) were added, and the reaction mixture was stirred overnight. Sodium bicarbonate 
was added to quench the reaction followed by extraction with dichloromethane and 
water (2 x 150 mL). Column chromatography with silica gel and a gradient elution with 
10–50% of ethyl acetate to hexanes afforded 27 as a white solid (552 mg, 74%).  
1H NMR (300 MHz, CDCl3) δ 4.23–4.05 (m, 9H), 2.50 (b s, 1H), 2.34 (t, J = 7.5 Hz, 4H), 
1.69–1.55 (m, 4H), 1.38–1.17 (b s, 60H), 0.88 (t, J = 5.9 Hz, 6H); MALDI–HRMS [M + 
Na]+ calcd: 619.60052, found: 619.60398. 
(R)-dibenzyl (2,3-bis(octadecyloxy)propyl) phosphate (28a). 
 
Compound 27 (50 mg, 0.08 mmol) was dissolved in anhydrous dichloromethane/THF 
(1:1) under nitrogen and cooled to 0°C. To the stirring mixture was added 1H-tetrazole 
(0.56 mL, 0.25 mmol, 0.45 M stock). Dibenzyl diisopropylphosphoramidite 16 (600 μL, 
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1.8 mmol) was then added dropwise. Stirring was continued for 30 min at 0 °C and then 
at room temperature for 1 h. At this point the reaction mixture was again cooled to 0° C 
and m-chloroperoxybenzoic acid (26 mg, 0.15 mmol, 57% purity) was added and stirring 
was continued for 1.5 h at room temperature. The reaction was quenched with the 
saturated sodium bicarbonate, extracted with dichloromethane and water (2 x 150 mL), 
dried with magnesium sulfate, filtered and concentrated under reduced pressure. 
Column chromatography with silica gel and gradient elution with 10–20% of ethyl 
acetate to hexanes afforded 10 (35 mg, 45%). 
The integrations values for the 1H NMR spectrum were close but did not completely 
match the actual values. This was due to the inability to separate starting material, 
product and phosphoramidite reagent using column chromatography, since they had 
same polarities. 
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Chapter 3: Design and Synthesis of Azide-Labeled Diacylglycerol 
(DAG) Analogues with Ether Chains  
 
Background and significance 
 Diacylglycerol is an important signaling lipid consisting of a glycerol molecule in 
which two hydroxyl groups have been replaced by two fatty acids at the sn-1 and sn-2 
position through ester bonds. (Figure 3.1.) Despite its simple structure, DAG is involved 
in important physiological and pathological processes. DAG is an important lipid 
intermediate in the biosynthesis and metabolism of various lipids78 and also acts as a 
second messenger in cell signaling.79,80 Malfunctions in DAG production and 
degradation  have been linked to the onset of various  diseases,  such  as  cancer80 and 
diabetes.81 
 Nishizuka and co-workers80 discovered protein kinase C (PKC) as the first 
receptor for DAG. Since then at least eleven different isozymes of protein kinase C 
(PKC) have been reported as DAG-binding receptors, thereby greatly increasing the 
number of proteins known to be modulated by direct interaction with DAG. PKCs have 
long been linked to tumorigenesis because of the central role they play in controlling 
proliferation, differentiation and apoptosis of different cell types.82,83,84  
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Figure 3.1. Structure of diacylglycerol molecule (DAG). 
 
PKCs are comprised of a family of serine/threonine kinases that are identified by 
the presence of two C1 domains, which form the DAG-binding modules. In addition to 
the two C1 domains, PKC enzymes also contain a C2 domain that recognizes anionic 
phospholipids on the membrane surface and are attracted to it through electrostatic 
interactions. Studying PKC binding interactions with DAG is complicated by factors 
including the fact that PKCs contain multiple binding domains that yield multivalent 
membrane association, different domains having varying DAG binding affinities and 
various isoenzymes of the PKC family show different specificities and affinities towards 
DAG. These subtle differences in lipid binding are known to significantly affect the 
regulation of protein function in biological pathways. As a result, characterization of 
these binding events becomes necessary.  
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Although PKC is one of the the most recognizable targets of DAG, other DAG 
receptors have also been reported. Recent studies have revealed that DAG also 
activates several other protein receptors. These include chimaerins,85 Ras guanyl-
releasing proteins (RasGRPs),  Munc13,86 protein kinase D (PKD),87 and DAG kinases. 
This clearly shows that cellular responses that are attributed to DAG can no longer be 
attributed solely to PKCs, which further highlights the complexity involved in studying 
the role of DAG as a signaling lipid in various cellular responses.  
Synthesis of DAG-based probes will allow for investigations of the biological 
activity at the molecular level and will help in understanding the role that DAG plays as 
a second messenger and as an important intermediate in lipid metabolism.  Towards 
this goal, various probes of DAG have been synthesized. Stahelin et al.88 have 
employed short-chained DAG and phorbol analogues in order to compare their binding 
affinities towards C1A and C1B domains of PKCε.  They observed that the C1A domain 
of PKCε has a stronger binding affinity  towards  DAG,  while  the  C1B  has  a  higher  
binding affinity  towards  phorbol  esters. I another study, Ananthanarayannan et al.79 
investigated the binding affinities of short chain DAG analogues toward C1A and C1B 
domains of PKCα.  They showed that the DAG analogues showed a high affinity for the 
C1A domain while no considerable affinity was observed for the C1B domain of PKCα. 
These studies also indicated that DAG analogs do not necessarily require the 
membrane for binding with proteins and hence can be employed for binding studies 
without the need of the membrane. 
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Synthesis DAG Analogues with ether tails 
Following the initial success of replacing the ester tails with ether tails in the DAG 
scaffold utilized for synthesizing PA analogues, we have attempted to extend this 
approach to develop the azide-tagged DAG scaffold with ether tails at the sn-1 and sn-2 
position. For this we modify the synthetic scheme such that an azide tag can be 
introduced in place of a hydrogen at the sn-1 position, and ether tails can be introduced 
at the sn-1 and sn-2 positions. (Figure 3.2.) The ether tails are used to avoid the 
migration of the sn-2 acyl chain to sn-3 position, which is known to become more 
prominent with the introduction of the azidomethyl moiety at the headgroup.26 It also 
avoids hydrolysis of acyl chains by various enzymes present in biological systems. 
 
Figure 3.2. Structure of azide-tagged DAG scaffold with ether chains, 42. 
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Although synthetic lipid probes have been utilized to study protein–lipid binding 
events, these investigations are often limited due to the absence of a modular 
approach, therefore requiring that each probe be synthesized in an individual manner. 
This has imposed limitations on the range of probes that can be developed for various 
studies. 
Our lab has successfully designed a DAG scaffold containing an azide tag at the 
sn-1 position which can be functionalized at a late stage of the synthesis with various 
reporter groups in order to obtain a wide array of DAG-based probes.26 The azide tag is 
placed at the sn-1 position as it has been found to be the most beneficial location for  
attaching the reporter molecule, since it places the reporter molecule close enough to 
the head group to allow for sensitive detection of binding, yet far enough so as not to 
interfere with the actual binding motif. We also made use of the same strategy and 
placed the azide tag at the sn-1 position for derivatization. The azide moiety has the 
advantage of being small in size and possesses bioorthogonal reactivity via 1,3-dipolar 
cycloadditions (“click” chemistry)15,89 or the Staudinger ligation.90,91 Since both 
approaches are highly selective and do not interfere with functionalities that exist in 
biological systems, they can be used for protein labeling and detection in complex 
biological samples. We will employ click chemistry to incorporate a variety of reporter 
molecules such as fluorophores and photoaffinity labels onto the core DAG scaffold 
structure. (Figure 3.3.) 
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Figure 3.3. Use of click chemistry to attach reporter tags to the DAG scaffold. 
 
One particular aim of this project was to develop bifunctional lipid probes for 
rapid identification of receptors that bind to DAG via ABPP.  The synthesis of such 
probes involves the introduction of two groups into the lipid structure–a cross-linking 
group such as a photoaffinity tag that selectively cross links to the receptor protein once 
the binding has occurred, as well as a secondary handle, usually an azide or alkyne, 
that is either used to selectively purify, identify and characterize the bound proteins by 
means of affinity purification or is used to visualize the proteins that have bound to 
DAG. (Figure 3.4.)  
 
Figure 3.4. An example of Activity Based Protein Profiling (ABPP) using a bifunctional   
                   probe to purify or visualize proteins bound to the lipid probe. 
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We have attempted to develop a bifunctional probe for ABPP that includes both a 
photoaffinity tag, benzophenone for photo-cross-linking, and an alkyne moiety as a 
secondary handle for purifying cross-linked proteins. (Figure 3.5.) The photoaffinity 
group used should be stable enough to avoid non-specific labeling, but reactive enough 
to modify residues of a bound protein. The role of a photoaffinity group is to label the 
proteins by photo-cross-linking to them. This aids in mapping the location of binding 
domains of the receptor proteins and in characterizing the protein–lipid binding 
interactions. For example, de Kroon and co-workers have developed an activity based 
probe derived from the structure of PC that contains a secondary azide tag for chemical 
modification and detection after binding.92 Picq and co-workers developed a 
photoaffinity-tagged PA probe that was used in the covalent labeling of type 4 cAMP-
phosphodiesterases (PDE4).93  
 
 
Figure 3.5. A bifunctional lipid probe. 
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The initial synthetic scheme, as shown in scheme A of figure 3.6., involved 
protecting the two alcohols of compound 29 with a p-methoxybenzyl (PMB) and a tert-
butyldiphenylsilyl (TBDPS) group, respectively, to obtain 31. Two different protecting 
groups were utilized in order to selectively modify the protected alcohol at the sn-1, 
position into an azidomethyl group and to protect the alcohol at the sn-3 position 
respectively. This was followed by the deprotection of the acetal group. Meng M. 
Rowland from our lab had been working on similar chemistry and had observed that the 
TBDPS group was removed during the deprotection of the acetal group. As a result, the 
synthetic scheme was modified (Scheme B, Figure 3.6.) so as to deprotect the acetal 
group first and then employ a selective protection of the primary alcohol of 33 with a 
TBDPS group. Once compound 32 was obtained, the next step involved installing the 
ether tails, utilizing potassium hydroxide (KOH) as a base to yield 34. 
Figure 3.6. Alternate synthetic routes followed for the synthesis of azide-tagged DAG      
       scaffold. 
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The basic conditions required for introducing the ether tails led to the removal of the 
TBDPS group. Since there are not many protection groups that can survive such basic 
conditions (potassium hydroxide), the PMB protecting group was selected to protect 
both the alcohols, thus introducing the ether chains before differentiating the two 
hydroxymethyl moieties. 
 The final synthetic scheme shown in figure 3.7. began with commercially available 
diethyl L-tartrate 35 and involved acetonide protection of diol 35 to furnish 36. The 
esters were then reduced using lithium aluminum hydride to yield diol 29. The alcohols 
of compound 29 were then protected with p-methoxybenzyl (PMB) protecting groups 
followed by the removal of the acetonide protecting group, which afforded diol 38. The 
ether tails were now introduced using 1-bromooctadecane and tetrabutylammonium 
iodide (TBAI) as catalyst yielding 39.76 Oxidative removal of the PMB protecting groups 
then afforded 40. Monotosylation of compound 40 furnished 41. The integration values 
in the 1H NMR spectrum were close but did not exactly match the expected values. 
There is a possibility that we might be getting a cyclized product in addition to the actual 
product. Next, 41 was directly converted to the azide tagged DAG scaffold 42.  Once 
the DAG scaffold is obtained it can then be used to attach various reporter groups such 
as fluorophores or affinity tags, or it can be reduced to an amine, which can then be 
reacted with the a y-shaped handle having a benzophenone and an alkyne tag to form 
the bifunctional probe 54.  
46 
 
 
Figure 3.7. Final synthetic scheme for azide-tagged DAG scaffold. 
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The synthesis of the y-shaped handle is shown in figure 3.8. and began with the 
coupling of 4-benzoylbenzoic acid to methyl-6-aminohexanoate hydrochloride to yield 
the ester 45. The methyl ester group of 45 was then hydrolyzed using 2 M sodium 
hydroxide and methanol to yield acid 46. After the cBz deprotection of Lysine N-cBz N-
Boc to yield the free amine 48, it was then coupled to the acid 46, which afforded 
compound 49. This was followed by the deprotection of the Boc group of compound 49 
to produce the corresponding free amine 50, which was then coupled to the acid with an 
alkyne handle 51 to yield compound 52. Next, the hydrolysis of methyl ester of 52 using 
2 M sodium hydroxide yielded the acid 53 having a benzophenone and an alkyne tag.  
The acid 53 formed can then be coupled to the DAG scaffold having an amine at the sn-
1 position 43 to form the bifunctional lipid probe 54. (Figure 3.9.) 
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Figure 3.8. Synthetic scheme for y-shaped handle having benzophenone as  
                   photoaffinity tag and an alkyne tag. 
 
Figure 3.9. Coupling of DAG scaffold with amine at the sn-1 position, 43 to the acid       
    having an affinity group and an alkyne handle, 53 to form bifunctional lipid probe 54. 
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Experimental 
General Considerations 
All reagents were purchased from Aldrich or  Acros and used as received. Dry solvents 
were obtained from a Pure Solv solvent delivery system purchased from Innovative 
Technology, Inc. Column chromatography was performed using 230–400 mesh silica 
gel purchased from Sorbent Technologies. NMR spectra were obtained using a Bruker 
AC250 spectrometer updated with a TecMag data collection system and a Varian 
Mercury 300 spectrometer. Mass spectra were obtained with the JEOL DART-AccuTOF 
spectrometer with high-resolution capabilities. Optical rotation values were obtained 
using a Perkin-Elmer 241 polarimeter. 
Synthetic Procedures 
(4R,5R)-diethyl 2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate (36). 
 
In a flame-dried flask diethyl L-tartrate 35 (6.76 mL, 39.5 mmol) was dissolved in 
benzene followed by the addition of p-toluenesulfonic acid (128 mg, 0.672 mmol). To 
the stirring solution was added 2,2-dimethoxypropane (6.03 mL, 48.6 mmol). The 
solution was refluxed at 80 °C for 3 h and the water formed in the reaction was collected 
in a Dean–Stark trap. After cooling the solution to room temperature, sodium carbonate 
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(200 mg, 1.89 mmol) was added and stirring was continued for 2 h. The solution was 
filtered and concentrated under reduced pressure. The next step was set up without 
further purification. 
((4S,5S)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)dimethanol (29).  
 
A solution of lithium aluminum hydride (3.0 g, 79 mmol) was dissolved in anhydrous 
THF (70 mL) and cooled to 0 °C and kept under nitrogen. The crude mixture from above 
step was dissolved in anhydrous THF (20 mL) and added dropwise to the reaction over 
a period of 30 min. The reaction mixture was stirred at 0 °C for 1 h, then at room 
temperature for 1 h, and was then cooled back to 0 °C at which point the reaction was 
quenched by the dropwise addition of 3 mL water, 3 mL of 10% NaOH, and 9 mL more 
of water. Stirring was continued for 30 min followed by the addition of anhydrous 
magnesium sulfate and stirring was continued for an additional 1 h. The solution was 
filtered and concentrated under reduced pressure. Column chromatography with silica 
gel and gradient elution with 3 to 5% methanol to dichloromethane afforded 29 as a 
clear oil (3.8 g, 63% over 2 steps). 
Characterizations matched those reported in the literature.94 
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((4S,5S)-4,5-bis(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane (37).  
 
Sodium  hydride  (0.548 g,  0.024  mmol)   dissolved  in  N,N-dimethylformamide (50 
mL) was taken in a round bottom flask under nitrogen and cooled to 0 °C.  Diol 29 (4.4 
g, 0.024 mmol) dissolved in DMF (10 mL) was added dropwise into the reaction mixture 
over a period of 30 min.  The  reaction  was  stirred  at   0 °C for 1 h and then p-
methoxybenzyl chloride (PMBCl, 1.9 mL, 0.024  mol)  was  added  to  the  solution  at  0 
°C  and stirred  at  room  temperature  overnight.  The reaction was quenched with 
water and extracted with dichloromethane and water, the organic layer was dried over 
magnesium sulfate, filtered and the solvent was removed under reduced pressure. This 
formed mono PMB protected alcohol.  
The reaction was set up again to form the di-PMB protected product. Sodium hydride  
(0.548 g,  0.024  mmol)   dissolved  in  N,N-dimethylformamide (50 mL) was taken in a 
round bottom flask under nitrogen and cooled to 0 °C.  The mono PMB protected 
alcohol from last step was dissolved in DMF (10 mL) and added dropwise into the 
reaction mixture over a period of 30 min.  The  reaction  was  stirred  at   0 °C for 1 h 
and then p-methoxybenzyl chloride (PMBCl, 1.9 mL, 0.024  mol)  was  added  to  the  
solution  at  0 °C  and stirred  at  room  temperature  overnight.  The reaction was 
quenched with water and extracted with dichloromethane and water, the organic layer 
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was dried over magnesium sulfate, filtered and the solvent was removed under reduced 
pressure to afford diPMB diol 37 as yellow oil. 
The next step was set up without further purification. 
(2S,3S)-1,4-bis((4-methoxybenzyl)oxy)butane-2,3-diol (38).  
  
Compound 37 from last step was dissolved in methanol (40 mL) and p-toluenesulfonic 
acid (1.9 g, 3.67 mmol) was added and the reaction mixture was stirred at room 
temperature overnight.  The  reaction  was then quenched  with  saturated  sodium 
bicarbonate  followed  by  extraction  with  dichloromethane  and  water.  Column 
chromatography with silica gel and gradient elution with 2_4% methanol to 
dichloromethane afforded 38 as a yellow solid (2.6 g, 27% over 2 steps).  
1H NMR (300 MHz, CDCl3) δ 7.28–7.14 (m, 4H), 6.92–6.77 (m, 4H), 4.52–4.35 (m, 4H), 
3.87–3.71 (m, 8H), 3.61–3.42 (m, 4H), 3.10–2.96 (s, 2H), HRMS [M + H]+ calcd: 
362.17294, found 363.18421 
4,4'((((2S,3S)2,3bis(octadecyloxy)butane1,4diyl)bis(oxy))bis(methylene))bis(meth- 
-oxybenzene) (39). 
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Compound 38 (130 mg, 0.34 mmol) was dissolved in dry benzene (4mL) followed by the 
addition of 1-bromooctadecane (359 mg, 1.08 mmol), potassium hydroxide (81 mg, 1.44 
mmol) and a catalytic amount of tetrabutylammonium iodide (TBAI).  The reaction was 
refluxed overnight at 105 °C and a Dean–Stark trap was used to collect water formed in 
the reaction. Column chromatography with silica gel and a gradient elution with 0–10% 
ethyl acetate to hexanes afforded 39 as a white solid (241 mg, 77%). 
1H NMR (300 MHz, CDCl3) δ  7.23 (d, J = 8.60 Hz, 4H), 6.85 (d, J = 8.65 Hz, 4H), 4.46–
4.40 (m, 4H), 3.82–3.76 (m, 6H), 3.66–3.54 (m, 6H), 3.54–3.38 (m, 4H), 1.60–1.46 (m, 
4H),  1.38–1.14 (b s, 60 H), 0.88 (t, J = 6.88 Hz, 6H);  MALDI–HRMS [M + Na]+ calcd: 
889.72611, found: 889.72091. 
(2S,3S)-2,3-bis(octadecyloxy)butane-1,4-diol (40). 
 
Compound 39 (875 mg, 1.01 mmol) was dissolved in dichloromethane (32 mL) and 
water (3.2 mL), 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (812 mg, 3.83 mmol) 
was added, and the reaction mixture was stirred overnight. Sodium bicarbonate was 
added to quench the reaction followed by extraction with dichloromethane and water (2 
x 100 mL). Column chromatography with silica gel and a gradient elution with 10–50% 
ethyl acetate to hexanes afforded 40 as a white solid (2752 mg, 44%).  
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1H NMR (300 MHz, CDCl3) δ 3.93–3.45 (m, 10H), 2.49 (s, 2H), 1.73–1.45 (m, 4H), 
1.47–1.13 (b s, 60H), 0.88 (t, J = 6.6 Hz, 6H); MALDI–HRMS [M + Na]+ calcd: 
649.61108, found: 649.61458. 
(2S,3S)-4-hydroxy-2,3-bis(octadecyloxy)butyl 4-methylbenzenesulfonate (41). 
 
Compound 40 (56 mg, 0.09 mmol) was suspended in anhydrous dichloromethane (10 
mL). With stirring was added silver(I)oxide (34 mg, 0.15 mmol), tosyl chloride (20 mg, 
0.11 mmol), and crushed potassium iodide (32 mg, 0.19 mmol). The reaction was 
stirred at room temperature overnight. Column chromatography with silica gel and a 
gradient elution with 10–35% ethyl acetate to hexanes afforded 41 as a white solid (16 
mg, 23%).  
1H NMR (300 MHz, CDCl3) δ  7.86–7.47 (m, 2H), 7.30–7.40 (m, 2H), 4.37–3.99 (m, 1H), 
3.98–3.86 (m, 1H), 3.83–3.66 (m, 2H), 3.60–3.46 (m, 6H),  2.49 (m, 3H), 2.17 (m, 1H), 
1.66–1.41 (m, 4H), 1.25 (b s, 60 H), 0.85 (m,  6H);  MALDI–HRMS [M + Na]+ calcd: 
803.61993, found: 803.61438. 
(2S,3S)-4-azido-2,3-bis(octadecyloxy)butan-1-ol (42). 
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Compound 41 (16 mg, 0.02 mmol) was dissolved in ethyl acetate (20 mL) and sodium 
azide (40 mg, 0.19 mmol) was added. The reaction was refluxed at 85 °C overnight. 
The solvent was concentrated under reduced pressure. Column chromatography with 
silica gel and a gradient elution from 15–50% ethyl acetate to hexanes afforded 42 as a 
colorless oil (12 mg, 80%). 
1H NMR (300 MHz, CDCl3) δ 4.01–4.85 (m, 3H), 3.79–3.71 (m, 1H), 3.51–3.40 (m, 3H), 
1.71–1.47 (m, 6H), 1.42–0.98 (b s, 66H), 0.88 (t, J = 6.7 Hz, 6H) 
Due to the low solubility of the product, the integration values in the 1H NMR spectrum 
were close but did not exactly match the expected values.  
 
methyl 6-(4-benzoylbenzamido)hexanoate (45). 
 
4-Benzoylbenzoic acid (0.9 g, 3.98 mmol) was dissolved in dichloromethane (70 mL) 
and to the stirring solution was added 4-dimethylaminopyridine (0.63 g, 5.17 mmol) 
under nitrogen.  To a solution of methyl 6-aminohexanoate hydrochloride (0. 72 g, 0.817 
mmol) in dichloromethane (70 mL) was added N-methylmorpholine (4.35 mL, 39.8 
mmol).  Both the solutions were combined and EDCl (0.99 g, 10.34 mmol) was added to 
the reaction mixture.  The reaction was stirred at room temperature overnight.  Column 
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chromatography on silica gel and a gradient elution with 25–50% ethyl acetate to 
hexanes afforded 45 (1.29 g, 91%). 
1H NMR (300 MHz, CDCl3) δ 7.95–7.89 (m, 2H), 7.81–7.73 (m, 4H), 7.68–7.54 (m, 1H), 
7.51–7.43 (m, 2H), 7.10 (t, J = 5.67, 1H), 3.64 (s, 3H), 3.56–3.27 (m, 2H), 2.31 (t, J = 
7.36,  2H), 1.75–1.56 (m, 4H), 1.47–1.37 (m, 2H); MALDI–HRMS [M + Na]+ calcd: 
376.1525, found: 376.1548 
6-(4-benzoylbenzamido)hexanoic acid (46). 
 
The ester 45 (303 mg, 0.598 mmol) was dissolved in methanol (16 mL) and 2 M sodium 
hydroxide (16 mL) was added. The solution was stirred at room temperature overnight.  
Solvent was removed and the crude product was extracted with dichloromethane and 2 
M hydrochloric acid (2 x 100 mL), dried with magnesium sulfate, and concentrated 
under reduced pressure. Column chromatography with silica gel and a gradient solvent 
system of 50% ethyl acetate/hexanes afforded the acid 46 (351 mg, 74%). 
1H NMR (300 MHz, CDCl3) δ 7.89–7.76 (m, 6H), 7.64–7.56 (m, 1H), 6.51–6.45 (m, 2H), 
7.09–7.11 (m, 1H),  3.53–3.46 (m, 2H), 2.39 (t, J = 7.11,  2H), 1.75–1.62 (m, 4H), 1.51–
1.42 (m, 2H); MALDI–HRMS [M + Na]+ calcd: 362.1368, found: 362.1334. 
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(S)-methyl 2-amino-6-((tert-butoxycarbonyl)amino)hexanoate (48). 
 
Commercially available cBz-protected amine (1.38 g, 3.49 mmol) was dissolved in 
methanol (38 mL), and 10% palladium/carbon (138 mg) by weight was added.  The 
mixture was placed under hydrogen and stirred for 24 h at room temperature.  The 
reaction was filtered over Celite and the filtrate was concentrated under reduced 
pressure to afford the amine 48. The next step was set up without further purification.  
(S)-methyl 2-(6-(4-benzoylbenzamido)hexanamido)-6-((tert-butoxycarbonyl)amino) 
hexanoate (49). 
 
The amine (352 mg, 1.36 mmol) from the last step was dissolved in N,N-
dimethylformamide (4 mL).  To the stirring solution were added N-methylmorpholine 
(595 µL, 5.4 mmol) under nitrogen. To the acid 46 (460 mg, 1.36 mmol) in N,N-
dimethylformamide (4 mL) was added 4-dimethylaminopyridine (497 mg, 4.07 mmol). 
Both the solutions were combined and EDCl (780 mg, 4.07 mmol) was added. The 
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reaction was stirred at room temperature for 48h.  Column chromatography with silica 
gel with gradient solvent system of 100% ethyl acetate/hexanes afforded 49 (800 mg, 
100%). 
1H NMR (300 MHz, CDCl3) δ 7.84–7.74 (m, 2H), 7.74–7.62 (m, 4H), 7.57–7.42 (m, 1H), 
7.41–7.33 (m, 2H), 6.63 (s, 1H), 6.08 (m, 1H), 4.60–4.34 (m, 2H), 3.57 (s, 3H), 3.49–
3.29 (m, 2H), 3.03–2.87 (m, 2H), 2.15 (m, 2H), 1.68–1.45 (m, 8H), 1.37–1.24 (m, 11H), 
1.23–1.07 (m, 2H); MALDI–HRMS [M + Na]+ calcd: 604.2999, 604.2945. 
 
4-oxo-4-(prop-2-yn-1-ylamino)butanoic acid (51). 
 
Propargylamine (400 µL, 5.83 mmol) was dissolved in acetonitrile/N,N- 
dimethylformamide (10 mL/10 mL) at 0 °C under nitrogen. Succinic anhydride (584 mg, 
5.83 mmol) dissolved in acetonitrile (20 mL) was added to the stirring mixture. The 
reaction mixture was warmed to room temperature and run overnight at room 
temperature. The solvent was removed, the solid was washed with hexanes (2 x 100 
mL), and the solvent removed under reduced pressure to afford alkyne 51. 
Characterizations matched those reported in the literature.77 
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(S)-methyl2-(6-(4-benzoylbenzamido)hexanamido)-6-(4-oxo-4-(prop-2-yn-1-yl-
amino)butanamido)hexanoate (52). 
 
Compound 49 (343 mg, 0.71 mmol) was dissolved in dichloromethane (6.0 mL).  
Trifluoroacetic acid (6.0 mL) was added, and the solution was stirred at room 
temperature overnight.  The solvent was removed under reduced pressure and placed 
under vacuum for 24 h. 
Next, the crude product (459 mg, 0.77 mmol) was dissolved in N,N-dimethylformamide 
(4 mL).  To the stirring solution were added N,N-methylmorpholine (850 µL, 7.71 mmol) 
under nitrogen. To compound 51 (120 mg, 0.77 mmol) in N-dimethylformamide (4 mL) 
was added 4-dimethylaminopyridine (141 mg, 1.16 mmol). Both the solutions were 
combined and EDCl (221 mg, 1.16 mmol) was added. The reaction was stirred at room 
temperature for 48 h.  Column chromatography with silica gel and a gradient solvent 
system of 1–5% methanol/dichloromethane afforded 52 (316 mg, 83%). 
1H NMR (250 MHz, CDCl3) δ 7.98–7.94 (m, 2H), 7.84–7.79 (m, 4H), 7.76–7.60 (m, 1H), 
7.54–7.48 (m, 2H), 7.72 (m, 1H), 6.98 (m, 1H), 6.71–6.64 (m, 2H), 4.58–4.49 (m, 1H), 
3.02–3.99 (m, 2H), 3.70 (s, 3H), 3.54–3.46 (m, 2H), 3.30–3.13 (m, 2H), 2.60–2.45 (m, 
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4H), 2.33–2.28 (m, 2H), 2.05 (s, 1H), 1.81–1.66 (m, 4H), 1.56–1.33 (m, 8H); MALDI–
HRMS [M + Na]+ calcd: 641.2951, 641.2967. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Design and Synthesis of Metabolically Stabilized 
Phosphatidylinositol phosphate (PIPn) Analogues 
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Background and significance  
Phosphatidylinositol phosphates (PtdInsPns or PIPns) are phosphorylated 
derivatives of myo-inositol belonging to an important class of membrane signaling 
lipids.95,96  There are seven  isomers of  the PIPn family differing only in the degree of 
phosphorylation of the hydroxyl groups at the 3-, 4- and 5-positions of the myo-inositol 
rings. The role of PIPns as signaling lipids results from their ability to bind to receptors 
called peripheral proteins through non-covalent binding, resulting in the anchoring of the 
protein receptors onto the cell membrane surface. These binding events are known to 
regulate many important physiological pathways, generally   through   the   regulation   
of   protein   function   and   subcellular localization. They are known to play a crucial 
roles in numerous cellular functions such as vesicle trafficking, apoptosis, cell 
proliferation and metabolism.95,96,49a  Furthermore, misregulation of signaling pathways 
due to defects in binding and lipid composition results in a range of disease conditions, 
such as cancer, leukemia, diabetes, and Alzheimer’s.97,98  
Despite the significance of PIPn–protein binding, many of these binding events 
are poorly understood due to the complex nature of these interactions. The subtle 
differences in the structure of various isomers of PIPns can result in different binding 
affinities and specificities of these isomers towards the receptors. There are certain 
receptors that bind with high affinity towards a particular PIPn isomer, while others 
appear to be more promiscuous. The PIPns are also known to bind to a wide array of 
protein-binding domains, such as the PH,9 PX, FYVE, ENTH, ANTH, FERM, Tubby, and 
PROPPIN12 domains.10, 13,14 Variations exist even within the domain families, particularly 
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with the PH domains, where investigations have indicated that there are over 250 PH 
domains in humans.  While all the PH domains are currently not believed to bind to 
PIPns,  different PH domains have  been  shown  to  target  different  PIPn  isomers.14 In 
addition, the structural requirements for recognition also vary among receptors. There 
are certain receptors that require the presence of the membrane for binding because 
the receptor inserts a hydrophobic sequence into the hydrophobic membrane core, 
there are other receptors that show high affinity for isolated PIPns headgroups.2,99 In 
such cases, binding  is primarily driven by electrostatic attraction to the myo-inositol 
headgroup, with little-to-no dependence on the membrane environment. All these 
factors make studying PIPn–protein binding interactions challenging, primarily due to 
their complex structure and even more complex ways in which they interact with 
proteins. 
Amongst various PIPns, PI(3,4,5)P3 is an important signaling lipid found in higher 
eukaryotic cells.100 PI(3,4,5)P3 is known to play a central role in a plethora of 
downstream cellular processes. These signaling events include cell proliferation and 
transformation,101 cell  shape  and motility,102 insulin action and alteration of glucose 
transport.103 An important example involves  the conversion of PI (4,5)P2  to PI(3,4,5)3, 
by means of the forward and reverse reactions catalyzed by phosphoinositide 3-kinase  
(PI3K)98 and  the  phosphatase  PTEN,104  respectively. These conversions are known 
to control the activity of an important protein Akt (protein kinase B). Upon binding to 
PI(3,4,5)P3, Akt is activated via  phosphorylation, which results in the regulation of 
numerous  downstream  processes  such as cell apoptosis and cell survival. For this 
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reason, PI(3,4,5)P3 production must be tightly regulated to avoid abnormal cell growth. 
The importance of this transformation becomes more clear from the fact that PI3K105 
and PTEN106 are amongst the most commonly mutated enzyme and tumor   
suppressor,   respectively, in tumorigenesis. In order to understand the role  PI(3,4,5)P3 
plays in the signaling pathways and its effect on downstream processes, it is necessary 
to study PI(3,4,5)P3–protein binding interactions at the molecular level.  
In order to understand these binding interactions, synthetic probes can be used 
to identify the structure of the natural biomolecules, to detect PIPn activity by the utilizing 
repoter-derivetized probes and to identify receptors that bind to PIPns by developing 
affinity probes.  Due to the presence of various isomers of PIPns in nature, a modular 
approach that allows derivatization at a late stage from a common scaffold in order to 
obtain several PIPn isomer probes would be beneficial. Furthermore,  chemical  probe  
synthesis  will allow access to analogs with different structural features, such as those 
that consist of isolated lipid headgroups as well  as  others  those that  contain  the  full  
glycerolipid  backbone.  
 
 
 
Metabolically Stabilized Analogs of PIPns 
There has been great interest in developing metabolically stable analogs of PIPns 
that are resistant to enzymatic modification and retain the biological activity of the 
natural compound.  The primary focus has been on stabilizing the phosphate groups 
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present in various PIPns with phosphomimetic groups that are resistant to phosphate 
hydrolysis.  
The  initial  approach  to  generating  metabolically  stabilized  PIPns  involved  
the introduction  of  phosphorothioates  in  place  of  phosphate  moieties.  Potter and 
co-workers synthesized the first metabolically stabilized PIPn probe, Ins(1,4,5)PS3 39 55, 
(Figure 4.1.)  Since then, numerous phosphorothioate derivatives of different PIPns 
have been  synthesized. The disadvantage of using phosphorothioate derivatives is that 
they have reduced binding affinities compared to their natural analogues.41 This was 
shown by Prestwich  and  co-workers, who synthesized  an  analogue  of  PI(3)P  
containing  a phosphorothioate  group in  place  of  the  3-phosphate  group. The 
decrease in binding affinity has been  mainly attributed to  the  modified  pKa   and  
hydrogen-bonding  ability  of  phosphorothioate compared  to  phosphate.39,107 
Prestwich  and  co-workers  also  developed PI(3,4,5)P3  analogue 56  stabilized at the 
3-position to specifically instill resistance to the 3-phosphatase PTEN. This involved 
replacing the 3-phosphate group with a phosphorothioate  moiety.107  The resulting 
analogs exhibited similar and even slightly higher activity in the sodium transport assay 
compared to the unmodified lipid. Prestwich and co-workers also synthesized  
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Figure 4.1. Various metabolically stabilized PIPns analogues. 
 
PI(3,4,5)P3 analogs stabilized at the 5-position, 57 to instill resistance for the 5-
phosphatases SHIP1 and SHIP2. The analogue exhibited binding affinity to the PH 
domain of Grp1 comparable to unmodified PIP3  analogue.36b   
Phosphonate moieties can also be used to provide enzymatic resistance to 
PIPns. Prestwich and co-workers have synthesized a derivative of PI(4,5)P2 58, where  
they used a phosphonate linkage instead of a phosphodiester group to attach myo-
inositol with the lipid backbone.108 They have also synthesized a metabolically stabilized 
PI(3)P analogue where they replaced phosphate moieties on the myo-inositol 
headgroups with a methylene phosphonate 59.41   Methylene phosphonates also  
exhibited  weaker  binding  affinities compared  to  natural PIPns,  which is mainly due to  
the  higher second  pKa  of  a phosphonate  group compared  to  that  of phosphate.   
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In order to improve the binding affinity of the phosphomimetic groups toward the 
receptors, recently fluoromethylene phosphonate have been utilized to replace the 
phosphate in PIPns. The electron withdrawing nature of the fluorine group decreases 
the pKa  to match the second pKa  of the natural phosphate.43  Prestwich and co-
workers have successfully incorporated the fluoromethylene phosphonate group into  
the myo-inositol headgroup of PI(3)P  analog  60  and  into the phosphodiester  of  
PI(4,5)P2 61,109  In terms of binding affinities,  fluoromethylene  group  might  seem  
most suited for synthesizing metabolically stabilized analogs. However,  the  optimal  
approach  may  depend  upon  the  particular  system  being studied. 
Synthesis of Metabolically Stabilized PI(3,4,5)P3 Analogue 
 Our strategy for synthesizing metabolically stabilized PI(3,4,5)P3 analogue 
involved the incorporation of phosphorothioate groups in place of the phosphate groups 
at the 1, 2 and 3 position of the myo-inositol ring. For this, we utilized the same modular 
synthetic route used by our lab for the synthesis of regular PI(3,4,5)P3 and all other 
PIPns analogues. This involves the synthesis of a modular PIPn headgroup  scaffold 
tethered to an amino group that can then be conveniently derivetized by coupling 
chemistry at a later stage to form a range of functionalized headgroup analogs for use 
as probes.  
 The synthetic route to a headgroup phosphorothiorate analogue corresponding to 
PI(3,4,5)P3 76 attached to an amino group is detailed in figure 4.2. and first involves the 
synthesis of intermediate 68, from myo-inositol, as described previously by Bruzik and 
co-workers.110  In 2003, they reported an efficient synthesis of all seven PIPn  isomers, 
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which started with the synthesis of steriospecific myo-inositol-camphor acetal product 
64 through the reaction of myo-inositol 62 with D-camphor dimethyl acetal 71. The 
products so formed were selectively crystallized to obtain the 64 having required 
stereochemistry. Next, a tert-butyldiphenylsilyl  (TBDPS)  group  was introduced onto  
64  to yield  65  with  high  regioselectivity.  The compound  65  was  then used  to 
synthesized PI(3,4,5)P3 precursor 68,  containing benzoyl groups at the position 3,4, 
and 5 of the myo-inositol structure. This involved the introduction of benzoyl groups at 
position 4 and 5 of 65 to produce 66. Next, the acetal group was deprotected followed 
by the introduction of a third benzoyl group at position 3, to obtain the precursor 68. The 
remaining two hydroxyl groups were then protected with BOM groups to generate 69. 
This was followed by benzoyl deprotection to obtain 70. Next, phosphoramidite 
chemistry was used to introduce phosphorothioate moieties at position 3, 4, and 5 to 
afford 73. We obtained very low yields while attempting to install the phosphorothioate 
groups utilizing dibenzyl diisopropylphosphoramidite 72 and sulfur. We also attempted 
to utilize phenyacetaldisulfide instead of sulfur to obtain 73, but the reaction did not 
occur. We then went back to the original conditions, and next carried out silyl 
deprotection by tetra-n-butylammonium fluoride to produce 74 which also gave low 
yields.   
 Since low yields were obtained using phosphorothioate chemistry compared to 
the original synthesis utilizing phosphate groups, in the future, alternate routes will be 
explored for developing metabolically stabilized PIPns. 
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Figure 4.2. Synthetic scheme for phosphorothioate PI(3,4,5)P3 headgroup analogue. 
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Experimental 
General Considerations 
All reagents were purchased from Aldrich, Acro. and used as received. Dry solvents 
were obtained from a Pure Solv solvent delivery system purchased from Innovative 
Technology, Inc. Column chromatography was performed using 230 – 400 mesh silica 
gel purchased from Sorbent Technologies. NMR spectra were obtained using a Bruker 
AC250 spectrometer updated with a TecMag data collection system, a Varian Mercury 
300 spectrometer. Mass spectra were obtained with JEOL DART-AccuTOF 
spectrometer with high resolution capabilities. Optical rotation values were obtained 
using a Perkin-Elmer 241 polarimeter.  
Synthetic Procedures 
(1R,4R)-2,2-dimethoxy-1,7,7-trimethylbicyclo[2.2.1]heptanes (71). 
 
To a dry flask was added D-camphor (32.6 g, 0.21 mol), dry methanol (33 mL), 
trimethylorthoformate (165 mL, 1.51 mol) and concentrated sulfuric acid (0.32 mL, 
catalytic amount) The mixture was stirred at room temperature for 48 h, neutralized with 
sodium methoxide and concentrated. The resulting residue was dissolved in toluene, 
the precipitated sodium sulfate was filtered off, and the filtrate was concentrated to give 
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D-camphor dimethyl acetate 71. The crude product was used in the next step without 
further purification. 
(1'R,2R,3aR,4S,4'R,5R,6R,7S,7aS)-1',7',7'trimethylhexahydrospirobenzo[d][1,3] 
dioxole-2,2'-bicyclo[2.2.1]heptane]-4,5,6,7-tetraol (64). 
 
The crude from the above step was dissolved in dimethylsulfoxide (184 mL) and myo-
inositol (16.86 g, 93.6 mmol) was added followed by sulfuric acid (0.95 mL) addition. 
The resulting mixture was stirred for 3 h at 75 °C, neutralized with triethylamine and 
concentrated. To the obtained residue was added dimethylsulfoxide to a total weight of 
82 g, as well as chloroform (285 mL), methanol (17.9 mL), water (5.7 mL), and p-
toluenesulfonic acid (63 mg). The mixture was stirred overnight, neutralized with 
triethylamine, filtered and washed with CHCl3 to give crude product. Recrystallization 
from MeOH (0.1% triethylamine) gave pure product 64 as white solid.    
Characterization matched the literature.111 
(1'R,2R,3aR,4S,4'R,5R,6S,7S,7aR)-4-((tert-butyldiphenylsilyl)oxy)-1',7',7'-trimethyl- 
hexahydrospiro[benzo[d][1,3]dioxole-2,2'-bicyclo[2.2.1]heptane]-5,6,7-triol (65). 
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A solution of tetrol 64 (1.56 g, 4.96 mmol) and imidazole (473 mg, 6.95 mmol) in 
pyridine (17 mL) was treated with tert-butyl diphenylchlorosilane (TBDPSCl) (1.3 mL, 
6.95 mmol) at -10 °C. Then the reaction was warmed to 15 °C and stirred overnight. 
The mixture was concentrated and extracted with ethyl acetate from water. The organic 
layer was dried over magnesium sulfate and the solvent was removed by rotary 
evaporation. Column chromatography with silica gel and elution from 20 : 1 to 10 : 1, 
CH2Cl2 / CH3OH afforded triol 65 (1.7 gm, 62 %) as a white foam.  
Characterization matched literature.111 
(1'R,2R,3aR,4S,4'R,5R,6R,7R,7aS)-4-((tert-butyldiphenylsilyl)oxy)-5-hydroxy-
1',7',7'-trimethylhexahydrospiro[benzo[d][1,3]dioxole-2,2'-bicyclo[2.2.1]heptane]- 
6,7-diyl dibenzoate (66). 
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To a stirring solution of the triol 65 (1.6 g, 2.9 mmol) in pyridine (15.3 mL) and 
dichloromethane (2.7 mL) under nitrogen at -40 °C, was added benzoyl chloride (0.7 
mL, 6.12 mmol) dropwise, then the mixture was slowly warmed to room temperature for 
about 5 h. The mixture was concentrated and extracted with ethyl acetate and water. 
The organic layer was dried with magnesium sulfate and concentrated under reduced 
pressure. Column chromatography with silica gel and gradient elution from 15 : 1 to 10 : 
1 of hexanes to acetone afforded alcohol 66 (1.4 g, 66%) as a white foam.  
Characterization matched literature.110 
(1R,2R,3R,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-3,5,6-trihydroxycyclohexane-
1,2-diyl dibenzoate (67). 
OH
OTBDPS
OBz
BzO
HO
OH
 
To a stirring solution of the alcohol 66 (1.05 g, 1.38 mmol) in chloroform (10 mL) and 
water (0.37 mL), was added trifluoroacetic acid (1.07 mL, 13.9 mmol). The mixture was 
stirred at room temperature overnight, neutralized using triethylamine and concentrated 
under reduced pressure. Column chromatography with silica gel and gradient elution 
from 30 : 1 to 20 : 1 of dichloromethane to methanol, afforded the triol 67 (627 mg, 80%) 
as a white foam. 
 Characterization matched the literature.110 
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(1R,2R,3S,4R,5R,6R)-5-((tert-butyldiphenylsilyl)oxy)-4,6-dihydroxycyclohexane-
1,2,3-triyl tribenzoate (68) 
 
To a solution of the diol 67 (877 mg, 1.40 mmol) in dichloromethane (15 mL) under 
nitrogen, was added 4-dimethylaminopyridine (DMAP) (171mg, 1.39 mmol) and triethyl 
amine (0.59mL, 4.19 mmol) The reaction was cooled to 0 0C followed by the addition of 
benzoyl chloride (0.161 mL, 1.40 mmol). The reaction was run at 0 °C for 10 min and 
then at room temperature overnight. Solvent was removed under reduced pressure and 
column chromatography with silica gel and a gradient elution from 5:1 to 1:1 hexanes to 
acetone afforded alcohol 68 (1.02g, 73%) 
Characterization matched the literature.110 
(1R,2R,3S,4R,5R,6R)-5-((tert-butyldiphenylsilyl)oxy)-4,6-dihydroxycyclo -1,2,3-triyl 
tribenzoate (69). 
OBOM
OTBDPS
OBOM
OBz
BzO
BzO
 
To a solution of the diol 68 (120mg, 0.16 mmol) in dichloroethane (5.5 mL) under 
nitrogen, was added diisopropylethylamine (217 µL, 1.31 mmol) and benzyl 
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chloromethylether (182 µL, 1.31 mmol). The solution was refluxed for 24 h then cooled 
to room temperature. Another portion of diisopropylethylamine (217 µL, 1.31 mmol) and 
benzyl chloromethylether (182 µL, 1.31 mmol) were added, and the solution was 
refluxed for another 24 h. The solution was then extracted with dichloromethane and 
water. The organic layer was dried over magnesium sulfate and the solvent was 
removed under reduced pressure. Column chromatography with silica gel and gradient 
elution from 10:1 hexanes to acetone, afforded the product 69 (69 mg, 43%) as a light 
yellow solid.  
Characterization matched literature.112 
(1R,2S,3S,4R,5S,6R)-4,6-bis((benzyloxy)methoxy)-5-((tert-butyldiphenylsilyl)oxy) 
cyclohexane-1,2,3-triol (70). 
OBOM
OTBDPS
OBOM
OH
HO
HO
 
To a solution of the fully protected inositol 69 (1.03 g, 1.06 mmol) in methanol (40 mL) 
was added 2M sodium hydroxide solution (16 mL), the solution was then stirred at room 
temperature overnight. The solution was filtered, and the solvent removed under 
reduced pressure. The residue was extracted with dichloromethane and water and the 
organic layer was dried over magnesium sulfate. Evaporation of solvent under reduced 
pressure and column chromatography with silica gel and gradient elution from 6 : 1 to 3 
: 1 of hexanes to acetone, afforded the diol 70 (870 mg, 52%) as a light yellow gum.    
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Characterization matched the literature.112 
O,O,O',O',O'',O''-hexabenzylO,O',O''-((1R,2S,3S,4S,5S,6S)-4,6bis((benzyloxy) 
methoxy)-5-((tertbutyldiphenylsilyl)oxy)cyclohexane1,2,3triyl)triphosphorothioate 
(73). 
OBOM
OTBDPS
OBOM
O
O
OP
S
BnO
BnO
P
P S
BnO OBn
S
BnO
BnO
 
Compound 70 (80 mg, 0.60 mmol) was dissolved in anhydrous dichloromethane (12 
mL). 1H-tetrazole (11.8 mL, 5.32 mmol, 0.45 M stock) was added and the solution was 
cooled to 0 °C under nitrogen. Dibenzyl diisopropylphosphoramidite 72 (1.25 mL, 0.588 
mmol) was then added dropwise. Stirring was continued for 10 min at 0 °C and then at 
room temperature for overnight. The reaction mixture was cooled to 0 °C and sulfur 
(233 mg, 7.26 mmol), carbon disulfide (314 µL) and pyridine (314 µL) were added and 
stirring was continued for 24 h. The reaction was extracted with dichloromethane, dried 
with magnesium sulfate, and concentrated under reduced pressure. Column 
chromatography with silica gel and gradient elution from 50:1 hexanes to acetone to 
100 % acetone afforded 73 as a pale yellow oil (124 mg, 15%). 
1H NMR (300 MHz, CDCl3) δ 7.80–7.69 (m, 4H), 7.41–7.09 (m, 51H), 5.16–4.86 (m, 12 
H), 4.82–4.93 (m, 10H), 4.93–4.37 (m, 12 H), 4.33–4.18 (m, 1H), 4.11–4.02 (m, 3H), 
3.47(s, 1H),  1.13–1.02 (m, 11H). 
76 
 
O,O,O',O',O'',O''-hexabenzylO,O',O''-((1R,2S,3S,4S,5S,6S)-4,6-bis((benzyloxy) 
methoxy)-5-hydroxycyclohexane-1,2,3-triyl) triphosphorothioate (74). 
 
Compound 73 (53mg, 0.03 mmol) was dissolved in tetrahydrofuran and tetra-n-
butylammonium fluoride (TBAF) (110mg, 0.34 mmol) was added. The reaction was 
stirred at room temperature for 48 h. Solvent was removed and column chromatography 
with silica gel and gradient elution from  20% to 50 % acetone to hexanes afforded 74 
as a pale yellow oil (124 mg, 15%). 
1H NMR (300 MHz, CDCl3) δ 7.38–7.09 (m, 40H), 5.43–5.30 (m, 1H), 5.24–4.93 (m, 
10H), 4.93–4.82 (m, 3H), 4.80–4.67 (m, 2H), 4.67–4.62 (m, 1H), 4.62–4.58 (m, 1H),  
4.56–4.41 (m, 3H), 4.38–4.23 (m, 1H), 4.29–4.22 (m, 1H), 3.91–3.79 (m, 1H), 3.58–3.49 
(m, 1H).  
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